Barinthus Biotherapeutics (NASDAQ:BRNS) Releases Earnings Results, Beats Estimates By $0.14 EPS

Barinthus Biotherapeutics (NASDAQ:BRNS) posted its quarterly earnings data on Thursday. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.14, FiscalAI reports.

Barinthus Biotherapeutics Stock Up 0.1%

NASDAQ:BRNS traded up $0.00 during midday trading on Friday, reaching $0.65. The stock had a trading volume of 5,564 shares, compared to its average volume of 18,707. The firm has a fifty day simple moving average of $0.60 and a two-hundred day simple moving average of $0.76. Barinthus Biotherapeutics has a 12-month low of $0.51 and a 12-month high of $2.92. The stock has a market cap of $26.58 million, a P/E ratio of -0.40 and a beta of -0.44.

Analyst Ratings Changes

Separately, Weiss Ratings lowered shares of Barinthus Biotherapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, April 22nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $4.00.

Institutional Investors Weigh In On Barinthus Biotherapeutics

A hedge fund recently raised its stake in Barinthus Biotherapeutics stock. Renaissance Technologies LLC raised its holdings in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) by 115.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 143,100 shares of the company’s stock after acquiring an additional 76,800 shares during the quarter. Renaissance Technologies LLC owned 0.35% of Barinthus Biotherapeutics worth $100,000 as of its most recent filing with the SEC. 25.20% of the stock is owned by institutional investors and hedge funds.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.